Jeffrey Weber, MD, PhD

Weber says these treatments, such as ipilimumab plus nivolumab, or dabrafenib and trametinib, have seen marked improvements since 2009, and continue to become more important in the treatment paradigm of melanoma.

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, discusses keys to targeted therapies for melanoma. These keys lie in BRAF and MEK inhibitors and combining those drugs with immunologic therapies.